


What is claimed is:

1. A compound of Formula (I)



or a pharmaceutically acceptable salt or solvate thereof

wherein

$A^1$  and  $A^2$  are each independently  $C_{1-4}$ alkylene or a bond;

$A^3$  is  $C_{1-4}$ alkylene or  $C_{1-4}$ alkylidene;

$A^4$  is  $C_{1-4}$ alkylene or a bond and is attached to X,  $X^1$  or  $X^2$ ;

X,  $X^1$ ,  $X^2$  and  $X^3$  are independently C or CH;

J is  $C_{1-4}$ alkyl;

p is 0 or 1;

$R^1$  and  $R^2$  are independently H,  $C_{1-3}$ alkyl,  $C_{3-6}$ cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O- $C_{1-4}$ alkyl or  $C_{1-4}$ alkyl-N(H)C(O)O-;

said  $C_{3-6}$ cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with  $C_{1-4}$ alkyl,  $C_{1-3}$ alkoxy or halo;

or are independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazoliny, pyrazolidinyl,

pyridyl, pyrimidinyl, piperidinyl, piperazinyl,  
 morpholino, adamantyl, indolyl, isoindolyl, indolinyl,  
 quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl,  
 isoquinolinyl, dihydroisoquinolinyl and  
 tetrahydroisoquinolinyl, wherein said heterocyclic  
 moieties are optionally substituted with halo, C<sub>1-4</sub>alkyl,  
 C<sub>1-4</sub>alkoxy or cyano;

or wherein -A<sup>1</sup>-R<sup>1</sup> and -A<sup>2</sup>-R<sup>2</sup> together with the nitrogen to  
 which they are attached form pyrrolyl, pyrrolinyl,  
 pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl,  
 pyrazolyl, pyrazoliny, pyrazolidinyl, pyridyl,  
 pyrimidinyl, piperidinyl, piperazinyl, morpholino,  
 adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl,  
 dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl,  
 dihydroisoquinolinyl or tetrahydroisoquinolinyl and are  
 optionally substituted with halo, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy,  
 cyano or benzyl;

R<sup>3</sup> is H or C<sub>1-4</sub>alkyl;

m is 0 or 1;

R<sup>4</sup> and R<sup>5</sup> are independently hydrogen, cyano, halo, nitro or C<sub>1-3</sub>perfluoroalkyl;

wherein said R<sup>4</sup> or R<sup>5</sup> may be independently attached to X, X<sup>1</sup>,  
 X<sup>2</sup> or X<sup>3</sup>;

n is 0 or 1;

G is N, O or S;

G<sup>1</sup> is N or CH;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

both  $R^4$  and  $R^5$  are not attached to the same of said X,  $X^1$ ,  $X^2$  or  $X^3$ ;

if G is O or S, then m is 0;

if G is N, then m is 1;

5

if  $R^1$  is  $-N(H)C(O)OC_{1-4}alkyl$ ,  $C_{1-4}alkyl-N(H)C(O)O-$  or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to  $A^1$ , then  $A^1$  is  $C_{2-4}alkylene$ ;

10

if  $R^2$  is  $-N(H)C(O)OC_{1-4}alkyl$ ,  $C_{1-4}alkyl-N(H)C(O)O-$  or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to  $A^2$ , then  $A^2$  is  $C_{2-4}alkylene$ ;

15

if  $R^1$  is  $N(H)C(O)O-C_{1-4}alkyl$ ,  $C_{1-4}alkyl-N(H)C(O)O-$  or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo,  $C_{1-4}alkyl$ ,  $C_{1-4}alkoxy$  or cyano, then  $R^2$  is H or  $C_{1-3}alkyl$ ;

20

25

if  $R^2$  is  $-N(H)C(O)O-C_{1-4}alkyl$ ,  $C_{1-4}alkyl-N(H)C(O)O-$  or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl,

30

5 dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl,  
dihydroisoquinolinyl and tetrahydroisoquinolinyl,  
wherein said heterocyclic moieties are optionally  
substituted with halo, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy or cyano,  
then R<sup>1</sup> is H or C<sub>1-3</sub>alkyl;

if A<sup>4</sup>, R<sup>4</sup> or R<sup>5</sup> are attached to X, then X is C;

if A<sup>4</sup>, R<sup>4</sup> or R<sup>5</sup> are attached to X<sup>1</sup>, then X<sup>1</sup> is C;

if A<sup>4</sup>, R<sup>4</sup> or R<sup>5</sup> are attached to X<sup>2</sup>, then X<sup>2</sup> is C;

if R<sup>4</sup> or R<sup>5</sup> are attached to X<sup>3</sup>, then X<sup>3</sup> is C;

10 if R<sup>4</sup> is F and is attached to X and if A<sup>3</sup> is methylene, then -  
A<sup>1</sup>-R<sup>1</sup> and -A<sup>2</sup>-R<sup>2</sup> together with the nitrogen to which  
they are attached is not N-methyl-piperazinyl; and

15 if R<sup>4</sup> is F and is attached to X and if A<sup>3</sup> is methylene, then -A<sup>1</sup>-  
R<sup>1</sup> and -A<sup>2</sup>-R<sup>2</sup> together with the nitrogen to which they  
are attached is not tetrahydroquinolinyl.

2. A compound according to claim 1 wherein p is 0.

3. A compound according to claim 1 wherein G is N and G<sup>1</sup> is CH.

4. A compound according to claim 1 wherein G is S and G<sup>1</sup> is CH.

5. A compound according to claim 1 wherein G is N and G<sup>1</sup> is N.

20 6. A compound according to claim 1 wherein A<sup>1</sup> is a bond, R<sup>1</sup> is methyl, A<sup>2</sup> is a  
bond and R<sup>2</sup> is methyl.

7. A compound according to claim 1 wherein R<sup>3</sup> is H and m is 1.

8. A compound according to claim 1 wherein R<sup>4</sup> and R<sup>5</sup> are halo.

9. A compound according to claim 1 wherein R<sup>4</sup> is hydrogen.

25 10. A compound according to claim 1 wherein R<sup>4</sup> is fluoro.

11. A compound according to claim 1 wherein R<sup>4</sup> is cyano.

12. A compound according to claim 1 wherein R<sup>4</sup> and R<sup>5</sup> are each fluoro.

30 13. A compound according to claim 1 wherein D in relation to the four moieties to  
which it is attached has an absolute configuration of S; E in relation to the four  
moieties to which it is attached has an absolute configuration of S; and wherein

the hydrogen atom attached to D is in the *trans* configuration to the hydrogen atom attached to E.

14. A compound according to claim 1 wherein A<sup>3</sup> is C<sub>1-4</sub>alkylene.
15. A compound according to claim 1 wherein A<sup>3</sup> is C<sub>1-4</sub>alkylidene.
- 5 16. A compound according to claim 1 wherein A<sup>3</sup> is methylene.
17. A compound according to claim 1 wherein wherein A<sup>4</sup> is a bond.
18. A compound according to claim 1 wherein A<sup>4</sup> is methylene.
19. A compound according to claim 1 wherein A<sup>4</sup> is attached X<sup>1</sup>.
20. A compound according to claim 1 wherein A<sup>4</sup> is attached X.
- 10 21. A compound according to claim 1 wherein R<sup>4</sup> is attached X.
22. A compound according to claim 1 wherein A<sup>1</sup> is a bond, A<sup>2</sup> is a bond, R<sup>1</sup> is methyl and R<sup>2</sup> is methyl.
23. A compound according to claim 1 wherein R<sup>1</sup> is independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl,
  - 15 pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally
    - 20 substituted with halo, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy or cyano; A<sup>1</sup> is C<sub>1-4</sub>alkylene; R<sup>2</sup> is H or C<sub>1-3</sub>alkylene; and A<sup>2</sup> is a bond.
  24. A compound according to claim 1 wherein R<sup>1</sup> is independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinolinyl and tetrahydroisoquinolinyl; A<sup>1</sup> is C<sub>1-4</sub>alkylene; R<sup>2</sup> is H or C<sub>1-3</sub>alkylene; and A<sup>2</sup> is a bond.
  - 25 25. A compound according to claim 1 wherein R<sup>2</sup> is independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally
    - 30

substituted with halo, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy or cyano; A<sup>2</sup> is C<sub>1-4</sub>alkylene; R<sup>1</sup> is H or C<sub>1-3</sub>alkylene; and A<sup>1</sup> is a bond.

26. A compound according to claim 1 wherein R<sup>2</sup> is independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny; A<sup>2</sup> is C<sub>1-4</sub>alkylene; R<sup>1</sup> is H or C<sub>1-3</sub>alkylene; and A<sup>1</sup> is a bond.
27. A compound according to claim 1 wherein R<sup>1</sup> and R<sup>2</sup> are independently H, C<sub>1-3</sub>alkyl, C<sub>3-6</sub>cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O-C<sub>1-4</sub>alkyl.
28. A compound according to claim 1 wherein R<sup>1</sup> and R<sup>2</sup> are independently H, C<sub>1-3</sub>alkyl, or -N(H)C(O)O-C<sub>1-4</sub>alkyl.
29. A compound according to claim 1 wherein R<sup>1</sup> and R<sup>2</sup> are independently H, C<sub>1-3</sub>alkyl, C<sub>3-6</sub>cycloalkyl, phenyl, or -O-phenyl.
30. A compound according to claim 1 wherein R<sup>1</sup> and R<sup>2</sup> are independently H, C<sub>1-3</sub>alkyl, or are independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny.
31. A compound according to claim 1 wherein R<sup>2</sup> is H or C<sub>1-3</sub>alkyl and R<sup>1</sup> is C<sub>3-6</sub>cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O-C<sub>1-4</sub>alkyl.
32. A compound according to claim 1 wherein R<sup>2</sup> is H or C<sub>1-3</sub>alkyl and R<sup>1</sup> is N(H)C(O)O-C<sub>1-4</sub>alkyl.
33. A compound according to claim 1 wherein R<sup>2</sup> is H or C<sub>1-3</sub>alkyl and R<sup>1</sup> is C<sub>3-6</sub>cycloalkyl, phenyl or -O-phenyl.
34. A compound according to claim 1 wherein R<sup>2</sup> is H or C<sub>1-3</sub>alkyl and R<sup>1</sup> is selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny.
35. A compound according to claim 1 wherein R<sup>1</sup> is H or C<sub>1-3</sub>alkyl and R<sup>2</sup> is C<sub>3-6</sub>cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O-C<sub>1-4</sub>alkyl.
36. A compound according to claim 1 wherein R<sup>1</sup> is H or C<sub>1-3</sub>alkyl and R<sup>2</sup> is N(H)C(O)O-C<sub>1-4</sub>alkyl.
37. A compound according to claim 1 wherein R<sup>1</sup> is H or C<sub>1-3</sub>alkyl and R<sup>2</sup> is C<sub>3-6</sub>cycloalkyl, phenyl or -O-phenyl.

38. A compound according to claim 1 wherein wherein  $R^1$  is H or  $C_{1-3}$ alkyl and  $R^2$  is selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinolinyl and tetrahydroisoquinolinyl.

5 39. A compound according to claim 1 wherein  $-A^1-R^1$  and  $-A^2-R^2$  together with the nitrogen to which they are attached form pyrrolidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, tetrahydroquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with benzyl.

40. A compound according to claim 1 wherein

10  $A^1$  and  $A^2$  are each independently  $C_{1-4}$ alkylene or a bond;

$A^3$  is  $C_{1-4}$ alkylene;

$A^4$  is a bond and is attached to X or  $X^1$ ;

$R^1$  and  $R^2$  are independently H,  $C_{1-3}$ alkyl,  $C_{3-6}$ cycloalkyl, phenyl, -O-phenyl or -N(H)C(O)O- $C_{1-4}$ alkyl;

15 said  $C_{3-6}$ cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with  $C_{1-4}$ alkyl,  $C_{1-3}$ alkoxy or halo;

or are independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinolinyl and tetrahydroisoquinolinyl;

20

or wherein  $-A^1-R^1$  and  $-A^2-R^2$  together with the nitrogen to which they are attached form pyrrolidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, tetrahydroquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with benzyl;

25

$R^3$  is H or  $C_{1-4}$ alkyl;

m is 0 or 1;

30  $R^4$  is cyano or halo and is attached to X or  $X^1$ ;

n is 0;

X and X<sup>1</sup> are each C;

X<sup>2</sup> and X<sup>3</sup> are each CH;

G is N, O or S;

5 G<sup>1</sup> is N or CH;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

if G is O or S; then m is 0;

10 if G is N, then m is 1;

if R<sup>1</sup> is -N(H)C(O)OC<sub>1-4</sub>alkyl or said heterocyclic moiety  
wherein said heterocyclic moiety contains a nitrogen  
atom and said nitrogen atom is attached to A<sup>1</sup>, then A<sup>1</sup>  
is C<sub>2-4</sub>alkylene;

15 if R<sup>2</sup> is -N(H)C(O)OC<sub>1-4</sub>alkyl or said heterocyclic moiety  
wherein said heterocyclic moiety contains a nitrogen  
atom and said nitrogen atom is attached to A<sup>2</sup>, then A<sup>2</sup>  
is C<sub>2-4</sub>alkylene;

20 if R<sup>1</sup> is -N(H)C(O)O-C<sub>1-4</sub>alkyl or said heterocyclic moiety,  
then R<sup>2</sup> is H or C<sub>1-3</sub>alkyl;

if R<sup>2</sup> is -N(H)C(O)O-C<sub>1-4</sub>alkyl or said heterocyclic moiety,  
then R<sup>1</sup> is H or C<sub>1-3</sub>alkyl;


25 if R<sup>4</sup> is F and is attached to X and if A<sup>3</sup> is methylene, then -  
A<sup>1</sup>-R<sup>1</sup> and -A<sup>2</sup>-R<sup>2</sup> together with the nitrogen to which  
they are attached is not N-methyl-piperazinyl; and

if R<sup>4</sup> is F and is attached to X and if A<sup>3</sup> is methylene, then -A<sup>1</sup>-  
R<sup>1</sup> and -A<sup>2</sup>-R<sup>2</sup> together with the nitrogen to which they  
are attached is not tetrahydroquinolinyl.




41. *Trans*-2-[5-Cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane; *Trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]cyclopropane; *Trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-methyl-benzylaminomethyl]-cyclopropane; (1*S*,2*S*)-*trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]-cyclopropane;
- 5 (1*S*,2*S*)-*trans*-2-[5-cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-methyl-2-amino(isopropylcarbamoyl)ethylaminomethyl]-cyclopropane; *trans*-1-(*N*-Benzylaminomethyl)-2-[5-cyanoindol-3-yl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-3-phenylpropylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-2-(3-indolyl)ethylaminomethyl]-cyclopropane; *trans*-1-
- 10 (4-Benzyl-piperidin-1-ylmethyl)-2-[5-cyanoindol-3-yl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-dipropylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-methyl-phenylethylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-phenylethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-2-(2-methoxyphenyl)ethylamino]-cyclopropane; *trans*-2-
- 15 [5-Cyanoindol-3-yl]-1-[*N*-2-(3-methoxyphenyl)ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-2-(4-methoxyphenyl)ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-2-phenoxy-ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[pyrrolidin-1-yl-methyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(methylcarbamoyl)ethylamino methyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(ethylcarbamoyl)ethylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(propyl carbamoyl)ethylamino methyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(isopropylcarbamoyl)ethylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(methylcarbamoyl)propyl aminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(ethylcarbamoyl)propylaminomethyl]-cyclopropane; *Cis*-2-[5-Cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-(*N*-methylaminomethyl)cyclopropane; (1*S*,2*S*)-*trans*-2-[5-Cyanoindol-3-yl]-1-(*N*-methylaminomethyl)cyclopropane; *trans*-3-[2-(1-Dimethylamino-ethyl)-cyclopropyl]-1*H*-indole-5-carbonitrile; *trans*-3-[2-(1-Pyrrolidin-1-yl-ethyl)-cyclopropyl]-1*H*-indole-5-carbonitrile; (-)*Cis*-2-[5-Cyanoindol-3-yl]-1-(*N,N*-
- 20
- 25
- 30

- dimethylaminomethyl)cyclopropane; 5-(2-Dimethylaminomethyl-cyclopropyl)-1H-indole-3-carbonitrile; [2-(5,6-Difluoro-1H-indol-3-yl)-cyclopropylmethyl]-dimethyl-amine; *Trans*-2-[5-cyanoindol-3-yl]-1-(3-(N-methylamino)propyl)cyclopropane; S,S-*Trans*-2-[5-Cyanoindol-3-yl]-1-(trimethylammoniummethyl)cyclopropane trifluoroacetate; S,S-*trans*-2-[5-cyano-1-methylindol-3-yl]-1-(*N,N*-dimethylamino)-cyclopropane; S,S-*trans*-2-[5-cyano-1-ethylindol-3-yl]-1-(*N,N*-dimethylamino)-cyclopropane; or 6-(2-Dimethylaminomethyl-cyclopropyl)-1H-indole-3-carbonitrile or pharmaceutically acceptable salts or solvates thereof.
42. A pharmaceutically acceptable formulation comprising a compound according to claim 1.
43. A method of treating depression, anxiety disorders, premature ejaculation, urinary incontinence, chronic pain, obsessive-compulsive disorder, feeding disorders, premenstrual dysphoric disorder, hot flashes, panic disorders, posttraumatic stress disorder or social phobia comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.
44. A method of treating premature ejaculation comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.
45. A process for the preparation of a compound of Formula (d)




(d)

by reacting a compound of formula (b)




with a compound of formula (c)




in the presence of ethyl diazoacetate and toluene, wherein  $R^4$  is cyano, halo, nitro or  $C_{1-3}$ perfluoroalkyl and X is *p*-toluenesulfonyl, benzenesulfonyl, methanesulfonyl or trifluoromethanesulfonyl.


46. According to another embodiment of the eleventh aspect of the present invention is provided a process for the preparation of a compound of Formula (d')



by reacting a compound of formula (b)



with a compound of formula (c)



in the presence of tert-butyl diazoacetate and toluene, wherein  $R^4$  is cyano, halo, nitro or  $C_{1-3}$ perfluoroalkyl and X is *p*-toluenesulfonyl, benzenesulfonyl, methanesulfonyl or trifluoromethanesulfonyl.

47. A method of treating sexual dysfunction in a mammal in need thereof comprising the administration of a pharmaceutically acceptable salt or solvate of a compound according to claim 1 and an erectile dysfunction agent.
48. A method of treating sexual dysfunction in a mammal in need thereof comprising the administration of a pharmaceutically acceptable salt or solvate of a compound according to claim 1 and sildenafil.